awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35691210-6BF18842-27B2-44CA-8837-82F07327CF1C
Q35691210-6BF18842-27B2-44CA-8837-82F07327CF1C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35691210-6BF18842-27B2-44CA-8837-82F07327CF1C
CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
P2860
Q35691210-6BF18842-27B2-44CA-8837-82F07327CF1C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35691210-6BF18842-27B2-44CA-8837-82F07327CF1C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
3214248c97b0fbeea5189cad8a7883918ae6c03c
P2860
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.